Drug Trial Radar · NCT07297667
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 30, 2026
Primary completion
Dec 1, 2028
Study completion Sep 1, 2033
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- University of Calgary; Canadian Institutes of Health Research (CIHR); BioCanRx
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers
Conditions
- Alveolar Soft Part Sarcoma
- Renal Cell Carcinoma
- Triple Negative Breast Cancer
Interventions
FludarabineDrug
Assigned at enrollment
CyclophosphamideDrug
Assigned at enrollment
GCAR1Biological
Dose escalation
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the recommended phase II dose (RP2D), defined as the next lower dose below the maximum administered dose, of GPNMB directed CAR T cell therapyTime frame: 3 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada · Recruiting
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada · Recruiting
University Health Network
Toronto, Ontario, Canada · Recruiting
The Research Institute of the McGill University
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.